EP3666797

ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)

Filed

Aug 22, 2008

Technology

Chemistry · Pharmaceuticals +1

UPC cases

EPO proceedings

Ownership history

As recorded at the EPO. Transfers made after the opposition period are recorded in national registers and may be missing here.

Amgen Inc.since May 15, 2020

Abstract

Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Litigation history

Date	Case	Division	Type	Outcome	Parties
Mar 25, 2026	UPC CoA 528/2024	Court of Appeal	Appeal	Locked	Amgen Inc. +1

Additional proceedings on this patent

Start 14-day free trialOutcomes, the additional proceedings and the register history.Already a user? Sign in